Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

Francis J. Giles, Hagop M. Kantarjian, Jorge E. Cortes, Guillermo Garcia-Manero, Srdan Verstovsek, Stefan Faderl, Deborah A. Thomas, Alessandra Ferrajoli, Susan O'Brien, Jay K. Wathen, Lian Chun Xiao, Donald A. Berry, Elihu H. Estey

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences